Pedro At
25/04/16 10:34
Ha respondido al tema Farmas USA
Ir a respuesta
SRPT
Hoy tiene comite, esperando noticias !! se esperan positivas.. pero ya conocemos como actua FDA .(
As expected, Nasdaq halts trading in Sarepta Therapeutics (NASDAQ:SRPT) pending news of the outcome of today's Ad Comm review of eteplirsen for the treatment of Duchenne muscular dystrophy DMD amenable to skipping exon 51.It should be a lively affair since many DMD activists will be attending the meeting in order to pressure the committee to vote for approval despite the absence of definitive data proving efficacy
y para el 26 de mayo PDUFA (PDUFA goal date extended by standard extension period of three months to May 26, 2016)
ya veremos como salgo de esta..